|
|
| Line 1: |
Line 1: |
| - | {| class="wikitable sortable" style="float:left; margin-left: 10px;"
| |
| - | ! Title || Comment || Links WP || Category || Status
| |
| - | |-
| |
| - | | SARS-CoV-2 and COVID-19 Pathway|| Collaborative project for curation of biological processes <br/> involved in the COVID-19 disease after SARS-Cov-2 infection. || [https://www.wikipathways.org/index.php/Pathway:WP4846 WP4846] || SARS-CoV-2 Pathways || style="font-style: italic; color: blue;" | Approved
| |
| - | |-
| |
| - | | Hijack of Ubiquitination by SARS-CoV-2 || SARS-CoV-2 includes a novel Orf10 that interacts with <br/> multiple members of the Cullin 2 ubiquitin ligase complex. || [https://www.wikipathways.org/index.php/Pathway:WP4860 WP4860] || SARS-CoV-2 Pathways || style="font-style: italic; color: blue;" | Approved
| |
| - | |-
| |
| - | | Type I Interferon Induction and Signaling During SARS-CoV-2 Infection || The induction and signaling of type I interferon <br/> with specific SARS-CoV-2 protein and relevant drug. || [https://www.wikipathways.org/index.php/Pathway:WP4868 WP4868] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | COVID-19, thrombosis and anticoagulation || A commonly seen phenotype in patients suffering from Corona || [https://www.wikipathways.org/index.php/Pathway:WP4927 WP4927] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | Activation of NLRP3 Inflammasome by SARS-CoV-2 || Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome. || [https://www.wikipathways.org/index.php/Pathway:WP4876 WP4876] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor: <br/> Molecular mechanisms and potential therapeutic target || || [https://www.wikipathways.org/index.php/Pathway:WP4883 WP4883] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | COVID-19 AOP || Experimental pathway to investigate overlap of virus-host interaction and adverse outcome pathways || [https://www.wikipathways.org/index.php/Pathway:WP4891 WP4891] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | nsp9/nsp10-mediated SARS-CoV-2 pathogenesis || Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients <br/> reveal potential virulence factors influencing SARS-CoV-2 pathogenesis || [https://www.wikipathways.org/index.php/Pathway:WP4884 WP4884] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | LDLRAD4 pathway in COVID-19 || || [https://www.wikipathways.org/index.php/Pathway:WP4904 WP4904] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | Overview of perturbations to host-cell autophagy,<br/> induced by distinct proteins of SARS-CoV-2 || || [https://www.wikipathways.org/index.php/Pathway:WP4936 WP4936] || SARS-CoV-2 Pathways || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | Coronavirus lipid metabolism || Lipid metabolism alternations that are related to infection by the corona virus. || [https://www.wikipathways.org/index.php/Pathway:WP4853 WP4853] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | Host-pathogen interaction of human corona viruses - autophagy || || [https://www.wikipathways.org/index.php/Pathway:WP4863 WP4863] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | Host-pathogen interaction of human corona viruses - apoptosis || || [https://www.wikipathways.org/index.php/Pathway:WP4864 WP4864] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | SARS coronavirus and innate immunity || || [https://www.wikipathways.org/index.php/Pathway:WP4912 WP4912] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | ER stress response in Coronavirus infection || || [https://www.wikipathways.org/index.php/Pathway:WP4861 WP4861] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | Downregulation of ACE2 expression by SARS-CoV <br/>infection and SARS-CoV Spike protein || || [https://www.wikipathways.org/index.php/Pathway:WP4799 WP4799] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | Host-pathogen interaction of human <br/> corona viruses - MAPK signaling || || [https://www.wikipathways.org/index.php/Pathway:WP4877 WP4877] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | Host-pathogen interaction of human <br/> corona viruses - Interferon induction || || [https://www.wikipathways.org/index.php/Pathway:WP4880 WP4880] || Other coronaviruses || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | ACE Inhibitor Pathway |||| [https://www.wikipathways.org/index.php/Pathway:WP554 WP554] || ACE2 || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | | Metabolism of Angiotensinogen to Angiotensins (Reactome) || || [https://www.wikipathways.org/index.php/Pathway:WP2729 WP2729] || ACE2 || style="font-style: italic; color: orange;" | In Progress
| |
| - | |-
| |
| - | |}
| |
| - |
| |
| | === Pathway categories === | | === Pathway categories === |
| | The pathways on this portal are grouped in the following categories: SARS-CoV-2 Pathways, Other coronaviruses (e.g. MERS, SARS-CoV) and virus-host specific interactions (e.g. ACE2). | | The pathways on this portal are grouped in the following categories: SARS-CoV-2 Pathways, Other coronaviruses (e.g. MERS, SARS-CoV) and virus-host specific interactions (e.g. ACE2). |
The pathways on this portal are grouped in the following categories: SARS-CoV-2 Pathways, Other coronaviruses (e.g. MERS, SARS-CoV) and virus-host specific interactions (e.g. ACE2).
The list of Featured Pathways is not static and can be updated at any time. If you know of a pathway that should be added, please contact the administrator.
